Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors

European Journal of Pharmacology

Volumn 354, Issue 1, 1998, Pages 105-111

  Gourlet, Philippe ^a   Rathé, Jean ^a   De Neef, Philippe ^a   Cnudde, Johnny ^a   Vandermeers Piret, Marie Claire ^a   Waelbroeck, Magali ^a   Robberecht, Patrick ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

VIP (vasoactive intestinal peptide) analog; VIP1 PACAP receptor; VIP2 PACAP receptor

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; RECEPTOR SUBTYPE; RECOMBINANT RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENYLATE CYCLASE; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; ENZYME ACTIVATION; HUMANS; KINETICS; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; STIMULATION, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031687386     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00435-X     Document Type: Article

References (34)

1. Ambrosius, D., Casaretto, M., Gerardy-Schahn, R., Saunders, D., Brandenburg, D., Zahn, H., 1989. Peptide analogues of the anaphylatoxin C3a; syntheses and properties. Biol. Chem. Hoppe-Seyler 370, 217-227.
2. Andersson, P.O., Bloom, S.R., Mellander, S., 1984. Haemodynamics of pelvic nerve-induced penile erection in the dog: possible mediation by vasoactive intestinal polypeptide. J. Physiol. 350, 209-224.
3. Biancani, P., Beinfeld, M.C., Coy, D.H., Hillemeier, C., Walsh, J.H., Behar, J., 1988. Dysfunction of the gastrointestinal tract. Vasoactive intestinal peptide in peristalsis and sphincter function. Ann. New York Acad. Sci. 527, 546-567.
4. Bolin, D.R., Michalewsky, J., Wasserman, M.A., O'Donnell, M., 1995. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37, 57-66.
5. Caughey, G.H., Leidig, F., Viro, N.F., Nadel, J.A., 1988. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J. Pharmacol. Exp. Ther. 244, 133-137.
6. Ciccarelli, E., Vilardaga, J.-P., De Neef, P., Di Paolo, E., Waelbroeck, M., Bollen, A., Robberecht, P., 1994. Properties of the VIP/PACAP type II receptor stably expressed in CHO cells. Regul. Pept. 54, 397-407.
7. Franconi, G.M., Graf, P.D., Lazarus, S.C., Nadel, J.A., Caughey, G.H., 1989. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J. Pharmacol. Exp. Ther. 248, 947-951.
8. Goetzl, E.J., Sreedharan, S.P., Turck, C.W., Bridenbaugh, R., Malfroy, B., 1989. Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3-4-24-11). Biochem. Biophys. Res. Commun. 158, 850-854.
9. Gourlet, P., De Neef, P., Woussen-Colle, M.-C., Vandermeers, A., Vandermeers-Piret, M.-C., Robberecht, P., Christophe, J., 1991. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes. Biochim. Biophys. Acta 1066, 245-251.
10. 1 receptor agonists. Peptides 18, 1539-1545.
11. 1 receptor. Peptides 18, 1555-1560.
12. 2 receptor subclass. Peptides 18, 403-408.
13. Gourlet, P., Vandermeers, A., Robberecht, P., Deschodt-Lanckman, M., 1997d. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase, EC 3-4-24-11. Biochem. Pharmacol. 54, 509-515.
14. Gozes, I., Fridkin, M., 1992. A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model. J. Clin. Invest. 90, 810-814.
15. Gozes, I., Reshef, A., Salah, D., Rubinraut, S., Fridkin, M., 1994. Stearyl-norleucine vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. Endocrinology 134, 2121-2125.
16. Gozes, I., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, I.E., Davidson, A., Rubinraut, S., Fridkin, M., Brenneman, D.E., 1995. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273, 161-167.
17. Gressens, P., Hill, J.M., Gozes, I., Fridkin, M., Brenneman, D.E., 1993. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362, 155-158.
18. Gressens, P., Marret, S., Hill, J.M., Brenneman, D.E., Gozes, I., Fridkin, M., Evrard, P., 1997. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100, 390-397.
19. Ishihara, T., Shigemoto, R., Mori, K., Takahashi, K., Nagata, S., 1992. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8, 811-819.
20. 2-adrenoceptor protein. Trends Pharmacol. Sci. 18, 149-151.
21. 2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334, 3-8.
22. Motulsky, H.J., Mahan, L.C., 1984. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25, 1-9.
23. Musso, G.F., Patthi, S., Ryskamp, T.C., Provow, S., Kaiser, E.T., Velicelebi, G., 1988. Development of helix-based vasoactive intestinal peptides analogues: identification of residues required for receptor interaction. Biochemistry 27, 8174-8181.
24. 2-terminal histidyl residue. Mol. Cell. Endocrinol. 52, 97-103.
25. O'Donnell, M., Garippa, R.J., Rinaldi, N., Selig, W.M., Simko, B., Renzetti, L., Tannu, S.A., Wasserman, M.A., Welton, A., Bolin, D.R., 1994a. RO 25-1553: a novel, long-acting vasoactive intestinal peptide agonist: I. In vitro and in vivo bronchodilator studies. J. Pharmacol. Exp. Ther. 270, 1282-1288.
26. O'Donnell, M., Garippa, R.J., Rinaldi, N., Selig, W.M., Tocker, J.E., Tannu, S.A., Wasserman, M.A., Welton, A., Bolin, D.R., 1994b. RO 25-1553: a novel, long-acting vasoactive intestinal peptide agonist: II. Effect on in vitro and in vivo models of pulmonary anaphylaxis. J. Pharmacol. Exp. Ther. 270, 1289-1294.
27. Ottesen, B., Wagner, G., Virag, R., Fahrenkrug, J., 1984. Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br. Med. J. Clin. Res. Ed. 288, 9-11.
28. Robberecht, P., Coy, D.H., De Neef, P., Camus, J.-C., Cauvin, A., Waelbroeck, M., Christophe, J., 1986. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes. Eur. J. Biochem. 159, 45-49.
29. Salomon, Y., Londos, C., Rodbell, M., 1974. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58, 541-548.
30. Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P.H., Journot, L., 1993. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365, 170-175.
31. Svoboda, M., Tastenoy, M., van Rampelbergh, J., Goossens, J.-F., De Neef, P., Waelbroeck, M., Robberecht, P., 1994. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205, 1617-1624.
32. Usdin, T.B., Bonner, T.I., Mezey, E., 1994. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135, 2662-2680.
33. 1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim. Biophys. Acta 1357, 255-259.
34. Vertongen, P., Schiffmann, S.N., Gourlet, P., Robberecht, P., 1997. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18, 1547-1554.